The emerging biotechnology company uses a proprietary suite of tools for drug discovery of functional antibodies and proteins against multi-spanning membrane proteins, with a focus on GPCRs, ion channels, and transporters. MSM's early drug development services specialize in the internal pipeline of antibodies directed to GPCRs in the area of oncology, autoimmune, and metabolic therapies, with the goal of helping patients avoid and treat diseases such as blood cancers, solid tumors, graft-versus-host disease, autoimmune diseases, and respiratory diseases.